Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 17/20 | 0.82 |
| ▸ | CDK2 | P24941 | 3/20 | 0.82 |
| ▸ | CCND3 | P30281 | 3/20 | 0.82 |
| ▸ | GAK | O14976 | 1/20 | 0.82 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.82 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.82 |
| ▸ | FECH | P22830 | 1/20 | 0.82 |
| ▸ | CCND1 | P24385 | 1/20 | 0.82 |
| ▸ | CDK9 | P50750 | 1/20 | 0.82 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.82 |
| ▸ | CDK16 | Q00536 | 1/20 | 0.82 |
| ▸ | MAP3K1 | Q13233 | 1/20 | 0.82 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.82 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.82 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.82 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.82 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.82 |
| ▸ | CDK1 | P06493 | 5/20 | 0.79 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21036418 | 0.92 | CDK4 (0.85) | CDK4CDK2CCND3GAKCCNT1 | |
| SCHEMBL30176525 | 0.92 | CDK4 (0.89) | CDK4CDK2CCND3GAKCCNT1 | |
| SCHEMBL302331 | 0.92 | CDK4 (0.89) | CDK4CDK2CCND3GAKCCNT1 | |
| SCHEMBL21227657 | 0.92 | CDK4 (0.86) | CDK4CDK2CCND3GAKCCNT1 | |
| SCHEMBL31607892 | 0.92 | CDK4 (0.82) | CDK4CDK2CCND3GAKCCNT1 | |
| SCHEMBL1999434 | 0.91 | CDK4 (0.81) | CDK4CDK2CCND3GAKCCNT1 | |
| SCHEMBL302130 | 0.91 | CDK4 (0.88) | CDK4CDK2CCND3GAKCCNT1 | |
| SCHEMBL2684165 | 0.91 | CDK4 (0.81) | CDK4CDK2CCND3GAKCCNT1 | |
| SCHEMBL29988280 | 0.91 | CDK4 (0.81) | CDK4CDK2CCND3GAKCCNT1 | |
| SCHEMBL30176515 | 0.91 | CDK4 (0.88) | CDK4CDK2CCND3GAKCCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200277295-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF RIBOCICLIB AND ITS SALTS | FRESENIUS KABI ONCOLOGY LIMITED (IN) | 2020-09-03 | — | — | US | disclosed |
| US-10723739-B2 | Processes for the preparation of Ribociclib and intermediates thereof | APOTEX INC. (CA) | 2020-07-28 | — | — | US | disclosed |
| US-20190345163-A1 | Processes for the Preparation of Ribociclib and Intermediates Thereof | THE BANK OF NOVA SCOTIA (CA) | 2019-11-14 | — | — | US | disclosed |
| WO-2018051280-A1 | PROCESS FOR PREPARATION OF RIBOCICLIB, ITS ACID ADDITION SALTS | DR. REDDY’S LABORATORIES LIMITED (IN) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200277295-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF RIBOCICLIB AND ITS SALTS | SUCLG2, RRM2B, IDH1 | CDK4 44/4885CDK2 158/4885CCND3 911/4885 |
| US-10723739-B2 | Processes for the preparation of Ribociclib and intermediates thereof | RRM2B, RPIA, RTCB | CDK4 4/4885CDK2 14/4885CCND3 617/4885 |
| US-20190345163-A1 | Processes for the Preparation of Ribociclib and Intermediates Thereof | RRM2B, RPIA, RTCB | CDK4 4/4885CDK2 14/4885CCND3 617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.